Faron Pharmaceuticals Oy (LON:FARN) Reaches New 12-Month Low – What’s Next?

Faron Pharmaceuticals Oy (LON:FARN)’s stock price hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as GBX 53.50 and last traded at GBX 57.80, with a volume of 1874604 shares trading hands. The stock had previously closed at GBX 67.

Faron Pharmaceuticals Oy Stock Up 0.9%

The firm has a 50 day simple moving average of GBX 165.93 and a two-hundred day simple moving average of GBX 183.88. The stock has a market capitalization of £63.48 million, a P/E ratio of -2.05 and a beta of 0.36. The company has a quick ratio of 1.09, a current ratio of 1.45 and a debt-to-equity ratio of 922.55.

Insider Buying and Selling at Faron Pharmaceuticals Oy

In other Faron Pharmaceuticals Oy news, insider Jurriaan Dekkers sold 4,000 shares of the business’s stock in a transaction dated Monday, January 12th. The stock was sold at an average price of GBX 182, for a total transaction of £7,280. 4.05% of the stock is currently owned by corporate insiders.

Faron Pharmaceuticals Oy Company Profile

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.